166 related articles for article (PubMed ID: 14633945)
1. Coeliac disease: in vivo toxicity of the putative immunodominant epitope.
Fraser JS; Engel W; Ellis HJ; Moodie SJ; Pollock EL; Wieser H; Ciclitira PJ
Gut; 2003 Dec; 52(12):1698-702. PubMed ID: 14633945
[TBL] [Abstract][Full Text] [Related]
2. Characterizing one of the DQ2 candidate epitopes in coeliac disease: A-gliadin 51-70 toxicity assessed using an organ culture system.
Martucci S; Fraser JS; Biagi F; Corazza GR; Ciclitira PJ; Ellis HJ
Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1293-8. PubMed ID: 14624152
[TBL] [Abstract][Full Text] [Related]
3. Wheat peptide challenge in coeliac disease.
Sturgess R; Day P; Ellis HJ; Lundin KE; Gjertsen HA; Kontakou M; Ciclitira PJ
Lancet; 1994 Mar; 343(8900):758-61. PubMed ID: 7907731
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the putative immunodominant T cell epitopes in coeliac disease.
Ellis HJ; Pollock EL; Engel W; Fraser JS; Rosen-Bronson S; Wieser H; Ciclitira PJ
Gut; 2003 Feb; 52(2):212-7. PubMed ID: 12524402
[TBL] [Abstract][Full Text] [Related]
5. The toxicity of high molecular weight glutenin subunits of wheat to patients with coeliac disease.
Dewar DH; Amato M; Ellis HJ; Pollock EL; Gonzalez-Cinca N; Wieser H; Ciclitira PJ
Eur J Gastroenterol Hepatol; 2006 May; 18(5):483-91. PubMed ID: 16607142
[TBL] [Abstract][Full Text] [Related]
6. Coeliac disease: immunogenicity studies of barley hordein and rye secalin-derived peptides.
Wahab WA; Šuligoj T; Ellis J; Côrtez-Real B; Ciclitira PJ
Int J Exp Pathol; 2016 Aug; 97(4):303-309. PubMed ID: 27659035
[TBL] [Abstract][Full Text] [Related]
7. In vivo toxicity of a synthetic dodecapeptide from A gliadin in patients with coeliac disease.
Mantzaris G; Jewell DP
Scand J Gastroenterol; 1991 Apr; 26(4):392-8. PubMed ID: 1827928
[TBL] [Abstract][Full Text] [Related]
8. Antagonists and non-toxic variants of the dominant wheat gliadin T cell epitope in coeliac disease.
Anderson RP; van Heel DA; Tye-Din JA; Jewell DP; Hill AV
Gut; 2006 Apr; 55(4):485-91. PubMed ID: 16299041
[TBL] [Abstract][Full Text] [Related]
9. In vivo gluten ingestion in coeliac disease.
Ciclitira PJ; Ellis HJ
Dig Dis; 1998; 16(6):337-40. PubMed ID: 10207218
[TBL] [Abstract][Full Text] [Related]
10. Natural variants of α-gliadin peptides within wheat proteins with reduced toxicity in coeliac disease.
Japelj N; Suligoj T; Zhang W; Côrte-Real B; Messing J; Ciclitira PJ
Br J Nutr; 2020 Jun; 123(12):1382-1389. PubMed ID: 32100654
[TBL] [Abstract][Full Text] [Related]
11. Gliadin specific, HLA DQ2-restricted T cells are commonly found in small intestinal biopsies from coeliac disease patients, but not from controls.
Molberg O; Kett K; Scott H; Thorsby E; Sollid LM; Lundin KE
Scand J Immunol; 1997 Sep; 46(3):103-9. PubMed ID: 9315123
[TBL] [Abstract][Full Text] [Related]
12. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease.
Maiuri L; Ciacci C; Ricciardelli I; Vacca L; Raia V; Auricchio S; Picard J; Osman M; Quaratino S; Londei M
Lancet; 2003 Jul; 362(9377):30-7. PubMed ID: 12853196
[TBL] [Abstract][Full Text] [Related]
13. In vitro toxicity of gluten peptides in coeliac disease assessed by organ culture.
Shidrawi RG; Day P; Przemioslo R; Ellis HJ; Nelufer JM; Ciclitira PJ
Scand J Gastroenterol; 1995 Aug; 30(8):758-63. PubMed ID: 7481543
[TBL] [Abstract][Full Text] [Related]
14. IgA antibodies of coeliac disease patients recognise a dominant T cell epitope of A-gliadin.
Bateman EA; Ferry BL; Hall A; Misbah SA; Anderson R; Kelleher P
Gut; 2004 Sep; 53(9):1274-8. PubMed ID: 15306584
[TBL] [Abstract][Full Text] [Related]
15. An immunodominant DQ8 restricted gliadin peptide activates small intestinal immune response in in vitro cultured mucosa from HLA-DQ8 positive but not HLA-DQ8 negative coeliac patients.
Mazzarella G; Maglio M; Paparo F; Nardone G; Stefanile R; Greco L; van de Wal Y; Kooy Y; Koning F; Auricchio S; Troncone R
Gut; 2003 Jan; 52(1):57-62. PubMed ID: 12477760
[TBL] [Abstract][Full Text] [Related]
16. Toxicity of different wheat gliadins in coeliac disease.
Wieser H; Springer G; Belitz HD; Ashkenazi A; Idar D
Z Lebensm Unters Forsch; 1982; 175(5):321-6. PubMed ID: 6758408
[TBL] [Abstract][Full Text] [Related]
17. In vitro (organ culture) studies of the toxicity of specific A-gliadin peptides in celiac disease.
de Ritis G; Auricchio S; Jones HW; Lew EJ; Bernardin JE; Kasarda DD
Gastroenterology; 1988 Jan; 94(1):41-9. PubMed ID: 3335296
[TBL] [Abstract][Full Text] [Related]
18. Intestinal antibody pattern of coeliac disease: association with gamma/delta T cell receptor expression by intraepithelial lymphocytes, and other indices of potential coeliac disease.
Arranz E; Bode J; Kingstone K; Ferguson A
Gut; 1994 Apr; 35(4):476-82. PubMed ID: 8174984
[TBL] [Abstract][Full Text] [Related]
19. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope.
Anderson RP; Degano P; Godkin AJ; Jewell DP; Hill AV
Nat Med; 2000 Mar; 6(3):337-42. PubMed ID: 10700238
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease.
Leffler D; Schuppan D; Pallav K; Najarian R; Goldsmith JD; Hansen J; Kabbani T; Dennis M; Kelly CP
Gut; 2013 Jul; 62(7):996-1004. PubMed ID: 22619366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
